Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) (NCT04728893)

🧪 Interventions in This Study

• Nemtabrutinib (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (121 Sites)

Showing the first 25 of 121 sites.

• Highlands Oncology Group ( Site 2728) — Springdale, Arkansas
• University of California San Diego Moores Cancer Center ( Site 2717) — La Jolla, California
• Lundquist Institute for Biomedical Innovation at Harbor-UCLA-Hematology and Medical Oncology ( Site 2724) — Torrance, California
• Colorado Blood Cancer Institute ( Site 2726) — Denver, Colorado
• The University of Louisville, James Graham Brown Cancer Center ( Site 2729) — Louisville, Kentucky
• Mayo Clinic - Rochester ( Site 2706) — Rochester, Minnesota
• Astera Cancer Care ( Site 2732) — East Brunswick, New Jersey
• John Theurer Cancer Center at Hackensack University Medical Center ( Site 2704) — Hackensack, New Jersey
• Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 2708) — Fargo, North Dakota
• UT Southwestern-Harold C. Simmons Cancer Center ( Site 2730) — Dallas, Texas
• Medical Oncology Associates (Summit Cancer Centers) ( Site 2710) — Spokane, Washington
• Hospital Aleman ( Site 0102) — Ciudad Autonoma de Buenos Aires, Buenos Aires
• Centro de Educación Médica e Investigaciones Clínicas (CEMIC) ( Site 0103) — Buenos Aires, Buenos Aires F.D.
• Fundacion Estudios Clinicos ( Site 0112) — Rosario, Santa Fe Province
• FUNDALEU ( Site 0104) — Caba,
• Hospital Privado Universitario de Córdoba ( Site 0107) — Córdoba,
• Fundacion Centro Oncologico de Integración Regional-Medical Oncology ( Site 0110) — Mendoza,
• Nepean Hospital-Nepean Cancer Care Centre ( Site 0204) — Sydney, New South Wales
• Box Hill Hospital ( Site 0203) — Box Hill, Victoria
• Sir Charles Gairdner Hospital ( Site 0200) — Nedlands, Western Australia
• Hospital das Clinicas FMUSP-Pesquisa Clínica Hematologia ( Site 0303) — São Paulo, São Paulo
• Instituto Nacional do Cancer Jose Alencar Gomes da Silva INCA ( Site 0300) — Rio de Janeiro,
• BP - A Beneficencia Portuguesa de São Paulo ( Site 0302) — São Paulo,
• Hospital Paulistano - Amil Clinical Research ( Site 0311) — São Paulo,
• Arthur J.E. Child Comprehensive Cancer Centre ( Site 0401) — Calgary, Alberta

📞 Contact the Study Coordinator

Phone: (888) 577-8839

Email: Trialsites@msd.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Hematologic Malignancies

• Giving Chemotherapy for a Shortened Amount of Time Before a Stem Cell Transplantation — New York, New York
• A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies — San Francisco, California
• Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies With Alpha Beta TCell and B Cell Depletion Using the CliniMACS Device — Milwaukee, Wisconsin
• A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant — Basking Ridge, New Jersey
• Digital Health Intervention for Self-Management and Telemonitoring in Chimeric Antigen Receptor (CAR-T) Therapy — Duarte, California
• PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV) — Duarte, California

Explore by condition: All Hematologic Malignancies clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.